Plaque Psoriasis

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

This analysis is described as the first to identify predictive factors of oral candidiasis in individuals with psoriasis who are treated with bimekizumab.

In this study, investigators pointed to existing resources available for mental health care among those with various skin conditions.

In this analysis, investigators highlighted various disease-related views and experiences dermatologists may wish to consider among Latine patients with psoriasis.

In the inaugural episode of Skin of Color Savvy, Andrew Alexis, MD, MPH, and Shawn Kwatra, MD, discuss diagnosis and management of itch in skin of color.

This study’s investigators examined long-term risk of dementia and Alzheimer’s dementia in patients with psoriasis, highlighting several notable findings.

The field of dermatology saw a wide array of notable developments this year, with highlights including FDA approvals as well as notable clinical trial results.

In this case–control study, investigators identified relevant comorbidities among individuals with bullous pemphigoid before and after their diagnoses.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.

The VISIBLE study’s findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

These findings indicate that incorporating educational video materials for psoriasis improved engagement in the shared decision-making process.

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

This study highlighted that both PASI scores and systemic inflammation, assessed using GlycA levels, were linked with cardiovascular disease.

These retrospective, 52-week data highlight the efficacy and safety of bimekizumab for those with moderate-to-severe psoriasis.

These data were announced by Protagonist Therapeutics, resulting from the 2 pivotal ICONIC-LEAD and ICONIC-TOTAL studies on the oral peptide icotrokinra.

In this cross-sectional survey analysis, new insights were explored regarding clinical practice patterns and treatment outcomes within dermatology practices in the US.

These results point to the value of awareness among physicians and patients of the risk of psoriasis linked to immunotherapy during cancer care.

The oral therapy may address limitations including difficulty in application and adverse events with topical therapies.

In this Month in Review summary, some of the most notable advancements and developments in the field of dermatology were highlighted.

Risankizumab achieves significantly higher rates of skin clearance and improved quality of life versus deucravacitinib in matching-adjusted indirect comparison analysis.

In this analysis, investigators identified several markers such as monocyte-high-density lipoprotein cholesterol ratio and C-reactive protein values.